Because PVR and NECTIN2 can both act on TIGIT, compared to the currently popular PDL1/PDLD1 blockers, TIGIT may not only reverse the exhaustion state of CD8 T cells but may also improve the tumor immunosuppressive microenvironment to a certain extent. Here, CD8A is linked to neoplasm.